Verici Dx plc (63V)

Overview

Verici Dx plc is an immuno-diagnostics development company with a primary focus on the kidney transplantation market. Founded in 2020 and headquartered in Penarth, the United Kingdom, the company is dedicated to improving the lives of kidney transplant patients through the development of innovative prognostic and diagnostic tests. Verici Dx plc aims to address critical needs in transplant medicine by predicting the risk of rejection and graft failure, thus significantly contributing to the field of transplant diagnostics.

Products and Services

• Tutivia
  

  A post-transplant diagnostic test developed by Verici Dx plc, Tutivia aims to detect acute rejection, including cases of sub-clinical rejection, in kidney transplant patients. This test is significant for the early identification of rejection episodes, allowing for timely intervention and potentially improving transplant outcomes.

• Clarava
  

  As a pre-transplant prognosis test, Clarava is designed to assess the risk of early acute rejection in patients awaiting kidney transplants. By providing this crucial information before transplantation, Clarava helps in the optimization of donor-recipient matching and the personalization of immunosuppressive therapy, aiming to enhance the success rate of transplants.

• Protega
  

  Protega is a peripheral blood-based test being developed to predict the risk of fibrosis and long-term graft failure in kidney transplant patients. By forecasting these long-term outcomes, Protega could play a pivotal role in the monitoring and management strategies of transplant recipients, potentially extending graft life.